The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of ...

UnitedHealth weighs $1B deal for Banmedica - report. Chime Financial IPO demand blows past share supply ahead of pricing. U.S ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

CNBC's Angelica Peebles reports on news regarding vaccines.

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

The most recent trading session ended with Merck (MRK) standing at $81.35, reflecting a +2.55% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%.

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...